TP53 and endometrial cancer: Thus, scholars have proposed the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) method [4] and TransPORTEC method [5] to improve the TCGA molecular typing system, and the prognostic information obtained is basically consistent with the TCGA molecular typing system; that is, the prognosis associated with POLE hypermutant tumors is the best, that with MSI-H and TP53 wild-type/ no specific molecular profile (NSMP) tumors is intermediate, and that with TP53 mutant tumors is the worst.